Biosimilar Antibodies

Inolimomab is a monoclonal antibody targeting the α chain of the interleukin-2 receptor (IL-2R). This antibody has shown potential in early-stage research for enhancing survival rates in patients with acute graft-versus-host disease (aGVHD). Its mechanism involves the specific inhibition of IL-2R, a critical regulator in the activation and proliferation of T lymphocytes, which play a significant role in the pathogenesis of aGVHD.

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody engineered to target the extracellular domains of HER2 and HER3 with its two distinct Fab arms. This dual specificity facilitates the inhibition of downstream signaling pathways that are critical for tumor growth and survival, making it a valuable tool for research in cancer biology, particularly in studies focused on breast and gastric cancers.

Gosuranemab (BMS-986168) is a humanized IgG4 monoclonal antibody specifically designed to target and bind to the N-terminal residues 15-22 of the tau protein in humans. This antibody is primarily explored for its potential applications in Alzheimer’s disease research, focusing on its ability to interact with tau, a protein implicated in the pathogenesis of neurodegenerative disorders.

The Anti-CD36 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CD36, a transmembrane glycoprotein involved in fatty acid metabolism, phagocytosis, and angiogenesis. This antibody consists of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focusing on cardiovascular diseases, metabolic disorders, and immune response modulation.

Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 monoclonal antibody specifically designed to target the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein. This antibody binds with high specificity and affinity, making it a valuable tool for research focused on viral entry mechanisms, neutralization assays, and therapeutic intervention studies related to COVID-19.

CHS-114 (SRF-114) is a fully human IgG1 monoclonal antibody designed to specifically target CCR8. This antibody has demonstrated potential utility in research focused on head and neck squamous cell carcinoma (HNSCC). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control.

Volociximab (M200), a chimeric human/murine IgG4 monoclonal antibody, selectively targets integrin α5β1 with an EC50 of 0.2 nM. Integrin α5β1, a principal receptor for fibronectin, plays a crucial role in angiogenesis. Volociximab exhibits potent antiangiogenic and antitumor properties, effectively inhibiting the proliferation of human umbilical vein vascular endothelial cells (HUVECs). This antibody is instrumental in research focused on the mechanisms of angiogenesis and potential therapeutic strategies for cancer treatment.

Foralumab (NI-0401) is a potent, orally active human monoclonal antibody that specifically targets CD3. This antibody plays a crucial role in modulating immune responses. It has demonstrated efficacy in NSG mice reconstituted with human hematopoietic stem cells, making it an invaluable tool for research into immune regulation and potential therapeutic applications.

Elotuzumab is a monoclonal antibody that specifically targets the SLAMF7 receptor. While it demonstrates minimal antimyeloma activity as a monotherapy in cases of relapsed or refractory multiple myeloma (RRMM), its efficacy is significantly enhanced when used in conjunction with other antimyeloma agents. This combination therapy has been shown to improve both response rates and overall outcomes in multiple myeloma treatment.

Ralzapastotug (AB-308) is a monoclonal antibody of the IgG1 subclass designed to specifically target the TIGIT receptor (T cell immunoreceptor with Ig and ITIM domains). This antibody binds to the amino acid sequence 106-126 of the cellular prion protein PrP^C, indicating a precise specificity that may be critical in modulating immune responses. Ralzapastotug is particularly relevant in research focused on immune checkpoint pathways and could be instrumental in studies exploring therapeutic interventions in oncology and immunological disorders.

Sonavibart is a human monoclonal antibody of the IgG1κ subtype that specifically targets the hemagglutinin HA protein of influenza A virus. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a chimeric mouse monoclonal antibody of the IgG1 subclass, specifically designed to target the human CD220, also known as the Insulin Receptor. This antibody recognizes and binds to the insulin receptor, facilitating studies on receptor expression and function in various biological contexts. For accurate isotype control in experimental setups, it is recommended to use Mouse IgG1 kappa Isotype Control to ensure specificity and consistency in results.

Donzakimig is a monoclonal antibody designed to target and inhibit the activity of interleukin 13 (IL-13), interleukin 22 (IL-22), and albumin (ALB). This antibody is engineered for high specificity and affinity, making it an ideal tool for research into the biological roles and interaction mechanisms of these cytokines and proteins. Donzakimig is suitable for use in various immunological assays to explore the pathophysiological implications of IL-13, IL-22, and ALB in disease states, providing valuable insights for therapeutic development.

Osocimab (BAY 1213790) is a potent anti-FXIa monoclonal antibody, characterized by a dissociation constant (Ki) of 2.4 nM and a half-maximal effective concentration (EC50) of 0.2 nM. This antibody targets Factor XIa (FXIa), a key enzyme in the coagulation cascade, and its inhibition is associated with a reduced risk of thrombosis. Osocimab effectively inhibits thrombin generation and prolongs the activated partial thromboplastin time (aPTT), demonstrating significant anticoagulant properties. This makes it a valuable tool for studies focused on the regulation of blood coagulation and the development of therapeutic strategies for thrombotic disorders.

Imneskibart is a humanized IgG1κ monoclonal antibody specifically targeting IL-2RA. For experimental control, the recommended isotype control is Human IgG1 kappa Isotype Control.

Toripalimab is a selective, recombinant, humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. This antibody binds specifically to PD-1, effectively blocking its interaction with PD-L1 and PD-L2 ligands. Through this mechanism, Toripalimab disrupts the PD-1 mediated signaling pathway, which is critical in regulating the immune system's response to cancer cells. Clinically, Toripalimab has demonstrated significant anti-tumor activity across a range of malignancies, including melanoma, lung cancer, various digestive tract tumors, hepatobiliary and pancreatic cancers, neuroendocrine tumors, nasopharyngeal carcinoma, and urothelial carcinoma. This antibody is pivotal in research focused on immunotherapy and the immune evasion strategies of tumors.

Trastuzumab is a humanized IgG1 monoclonal antibody specifically designed for targeting and neutralizing HER2, a protein overexpressed in certain invasive breast cancers. This antibody is crucial for research focused on HER2-positive metastatic breast cancer and HER2-positive gastric cancer, providing a valuable tool for understanding disease mechanisms and developing therapeutic strategies.

The Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets Melanotransferrin, also known as CD228. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145.16 kDa. For isotype control experiments, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the biological functions and pathological roles of Melanotransferrin/CD228.

MEDI-3617 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Angiopoietin-2 (Ang2/ANGPT2). This antibody is comprised of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For isotype control, it is recommended to use Human IgG2 kappa, Isotype Control. MEDI-3617 is designed for precise binding and neutralization of Ang2, making it highly relevant for research into vascular development and angiogenic processes.

Ansuvimab-zyk is a recombinant human monoclonal IgG1 antibody designed to target and neutralize Zaire ebolavirus. It functions by specifically binding to the viral glycoprotein, thereby inhibiting the virus's ability to enter and infect host cells. This interaction is crucial for preventing the spread of infection and is a key mechanism in its antiviral efficacy against Zaire ebolavirus.

Pritumumab is a naturally derived human monoclonal antibody of the IgG1 kappa subclass, initially isolated from a regional draining lymph node in a patient diagnosed with cervical carcinoma. This antibody specifically targets vimentin displayed on the surface of malignant tumor cells. It is particularly useful in the study of glioblastoma, offering potential insights into the pathology and therapeutic targeting of this aggressive cancer type.

Demcizumab (OMP 21M18) is a monoclonal antibody targeting DLL4, a critical regulator in the Notch signaling pathway. This antibody acts as a potent inhibitor of the Notch pathway, which plays a significant role in cell differentiation, proliferation, and apoptosis. The inhibition of this pathway by Demcizumab has demonstrated efficacy in various cancer models, both as a standalone treatment and in combination with chemotherapy. This makes it a valuable tool for research in cancer biology, particularly in studies exploring the role of Notch signaling in tumorigenesis and therapeutic resistance.

The Anti-NKG2D/CD314 Antibody (1D11) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human NKG2D/CD314. This antibody selectively binds to the NKG2D receptor, a key player in immune cell activation. For accurate isotype control in experimental assays, it is recommended to use Mouse IgG1 kappa, Isotype Control. This antibody is ideal for use in research focused on immune response modulation and the study of diseases where NKG2D signaling is implicated.

Satumomab is a monoclonal antibody of the IgG4-G2a κ isotype, specifically targeting the tumor-associated glycoprotein 72 (TAG-72). This antibody is designed for the precise detection and study of TAG-72 expression in various cancer types, facilitating research into tumor biology and potential therapeutic targets.

Matuzumab (EMD 72000) is a humanized monoclonal antibody designed to target and inhibit the epidermal growth factor receptor (EGFR). By binding to EGFR, Matuzumab prevents its activation and the subsequent downstream signaling pathways, effectively inhibiting tumor growth. This antibody is utilized primarily in research focused on cancer biology, particularly in studies investigating the mechanisms of tumor progression and therapeutic intervention.

Alacizumab is a humanized monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target VEGFR2/KDR/CD309. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, resulting in a predicted molecular weight of 144.08 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. Alacizumab is applicable in research focused on angiogenesis and vascular biology due to its specificity in binding to VEGFR2/KDR/CD309, a critical receptor in vascular endothelial growth factor (VEGF) signaling pathways.

Cifurtilimab (SEA-CD40) is an agonistic, non-fucosylated human IgG1 monoclonal antibody that targets CD40, a co-stimulatory protein found on antigen-presenting cells. This antibody has been engineered to enhance immune activation and exhibits significant antitumor activities, making it a valuable tool for research in cancer immunotherapy.

Ripertamab (SCT400) is a recombinant, chimeric monoclonal antibody (mAb) composed of human and mouse sequences. This antibody is of the IgG1κ isotype and targets the CD20 antigen, a cell surface protein primarily expressed on B cells. Ripertamab is specifically designed for use in research focused on hematological malignancies, such as non-Hodgkin’s lymphoma (NHL), providing a valuable tool for studies aimed at understanding and potentially treating these diseases.

Lumiliximab, a recombinant anti-CD23 monoclonal antibody, effectively inhibits allergen-induced responses by targeting the CD23 receptor. This antibody serves as a crucial tool in immunological research, particularly in studies related to allergic reactions and immune regulation. Lumiliximab's specificity for CD23 makes it ideal for investigating the role of this receptor in various immunological processes and potential therapeutic applications.

Istiratumab (M-6495) is a bispecific monoclonal antibody designed to target both the Insulin-like Growth Factor 1 Receptor (IGF-1R) and the ErbB3 receptor. This antibody facilitates the degradation of these receptors via the proteasome pathway, a mechanism that may be critical in modulating cellular growth and survival pathways. Istiratumab is primarily used in cancer research, where it serves as a tool to investigate the role of IGF-1R and ErbB3 in tumor biology and therapeutic response.

Anvatabart is a human IgG1 κ monoclonal antibody targeting ERBB2. For accurate control experiments, it is recommended to use Human IgG1 kappa as an isotype control.

Atrosimab (ATM-001) is an engineered Fv-Fc1κ fusion protein that exhibits high-affinity binding to human TNF receptor 1 (TNFR1), demonstrated by an EC50 of 0.37 nM. This biologic effectively inhibits TNF-induced activation of TNFR1, highlighting its utility in the investigation of chronic inflammatory diseases. Atrosimab represents a valuable tool for researchers studying the molecular pathways involved in inflammation and immune response.

Brivestobart is a human monoclonal antibody of the IgG4κ subtype designed to target LAG3. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity makes Brivestobart suitable for research focused on the modulation of immune checkpoint pathways, particularly in the context of immunotherapy and cancer research.

Rulonilimab, a human IgG1 monoclonal antibody, selectively targets and binds to the programmed death-1 (PD-1) receptor, effectively inhibiting its interaction with PD-L1 and PD-L2. This inhibition disrupts downstream signaling pathways, thereby enhancing T-cell function and potentially exerting robust anti-tumor activity through immune checkpoint blockade. This antibody is designed for use in research focused on cancer immunotherapy and the modulation of immune responses.

Zolbetuximab (IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2, a tight junction protein predominantly expressed in certain epithelial cells. This antibody facilitates the selective eradication of Claudin-18.2-positive cells by engaging immune effector mechanisms. It is primarily utilized in scientific studies focused on gastrointestinal adenocarcinomas and pancreatic tumors, offering a critical tool for understanding and potentially targeting these malignancies.

The Anti-GPC-2 Antibody (CT3) is a chimeric mouse monoclonal antibody of the IgG1 kappa subtype, specifically designed to target human Glypican-2 (GPC-2). For accurate experimental control, it is recommended to use Mouse IgG1 kappa Isotype Control. This antibody serves as a vital tool for the detection and study of GPC-2 expression in various research applications.

Abiprubart is a human IgG4 κ monoclonal antibody targeting CD40. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Letolizumab (BMS-986004) is a monoclonal antibody engineered to specifically target CD40L. This antibody variant is designed as a mutant IgG1 isotype that lacks effector functions, notably Fc receptor binding and complement fixation capabilities. The primary therapeutic action of Letolizumab is to mitigate rejection and thromboembolism, effectively extending survival time in clinical settings. This makes it particularly valuable in research focused on immune response modulation and transplantation immunology.

Drozitumab (PRO 95780) is a human agonistic monoclonal antibody designed to specifically target and bind to the death receptor DR5. This interaction promotes apoptosis in tumor cells, thereby exhibiting potent antitumor activity. Drozitumab has demonstrated significant efficacy against rhabdomyosarcoma in research settings, making it a valuable tool for studies focused on this type of cancer.

The Anti-CLDN6 Antibody (DS-9606A) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells that specifically targets Claudin 6 (CLDN6). This antibody is composed of an IgG1 type heavy chain and a human kappa (huκ) type light chain, with a predicted molecular weight of 145.84 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research applications focusing on the role of CLDN6 in cellular tight junctions and its implications in various disease states.

Cosfroviximab (c13C6-FR1) is a chimeric monoclonal antibody derived from both mouse and human sources, designed to target the glycoprotein of the Ebola virus (EBOV-GP). This antibody is specifically engineered for high specificity and affinity towards EBOV-GP, making it an essential tool for research into the pathogenesis and potential treatments of Ebola virus infections.

Ofatumumab is a fully human monoclonal antibody targeting the CD20 antigen on B lymphocytes. It functions primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), effectively lysing CD20-positive B cells. This antibody demonstrates potent efficacy in eliminating CD20-positive tumor cells, including those resistant to other drugs with low CD20 expression levels. Ofatumumab is particularly valuable in the study of chronic lymphocytic leukemia (CLL), offering insights into therapeutic resistance and disease progression mechanisms.

Zovostotug is a monoclonal antibody that specifically targets human CD163, a member of the scavenger receptor cysteine-rich (SRCR) superfamily, type 1 M130. This antibody is designed for precision in binding to CD163, which is predominantly expressed on the surface of macrophages and is involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes. Zovostotug is an essential tool for researchers studying macrophage activation, inflammation processes, and the resolution of tissue damage, making it ideal for applications in immunology and cellular biology.

Encelimab is a monoclonal antibody targeting LAG-3 (Lymphocyte-activation gene 3). By inhibiting the interaction between LAG-3 and MHC class II molecules, Encelimab promotes T-cell activation and enhances immune responses. Studies have demonstrated that Encelimab, both as a monotherapy and in conjunction with an anti-PD-1 antibody, effectively reduces tumor volume in a lymphoma mouse model using A20 cell xenografts. This antibody is pivotal for research focused on immunotherapy and cancer immunology, particularly in understanding and manipulating T-cell responses in oncological models.

The Anti-CLEC14A Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CLEC14A, a marker implicated in angiogenesis and tumor biology. This antibody comprises an IgG1 heavy chain and a human kappa (huκ) light chain, exhibiting a predicted molecular weight of approximately 150 kDa. For isotype control in experimental procedures, the Human IgG1 kappa, Isotype Control is recommended. This product is essential for research focused on cancer, vascular biology, and related therapeutic development.

Samalizumab (ALXN 6000) is a humanized monoclonal antibody engineered to selectively target and bind to CD200, effectively inhibiting its interaction with the CD200 receptor (CD200R). This antibody is utilized in the study of multiple myeloma and B-cell chronic lymphocytic leukemia, offering a valuable tool for researchers exploring the pathophysiological roles and therapeutic potential of CD200-CD200R signaling in these hematological malignancies.